Nebularine

Nebularine

SCHEMBL745560

OC[C@H]1O[C@@H](n2cnc3cncnc32)[C@@H](O)[C@@H]1O

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 1/20 0.65
KDM4E B2RXH2 1/20 0.62
PKM P14618 1/20 0.62
DPP4 P27487 1/20 0.60
MEN1 O00255 1/20 0.60
SLC28A1 O00337 1/20 0.60
MAP3K7 O43318 1/20 0.60
SLC28A2 O43868 1/20 0.60
GAPDH P04406 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
MAPK1 P28482 1/20 0.60
ADORA2A P29274 1/20 0.60
ADORA2B P29275 1/20 0.60
ADORA1 P30542 1/20 0.60
STAT6 P42226 1/20 0.60
PI4KA P42356 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PI4K2B Q8TCG2 1/20 0.60
DOT1L Q8TEK3 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nebularine SCHEMBL9644429 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL29799158 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL93409 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL1894168 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL10666450 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL27552329 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL29362246 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL742475 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
SCHEMBL25170484 0.99 ADA (0.64) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL8895399 0.99 ADA (0.64) ADAKDM4EPKMDPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229772-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF Univerzita Palackého v Olomouci (CZ) 2017-10-18 EP claimed
EP-3229771-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF Univerzita Palackého v Olomouci (CZ) 2017-10-18 EP claimed
WO-2016091236-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2016-06-16 WO claimed
WO-2016091235-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2016-06-16 WO claimed
CN-110615818-B Synthesis method of fludarabine and nelarabine 江西科技师范大学 2023-02-17 CN disclosed
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-02-04 US disclosed
CN-110615818-A Synthesis method of fludarabine and nelarabine 江西科技师范大学 2019-12-27 CN disclosed
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-10-16 US disclosed
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-23 US disclosed
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-16 US disclosed
EP-3229772-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF Univerzita Palackého v Olomouci (CZ) 2017-10-18 EP disclosed
EP-3229771-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF Univerzita Palackého v Olomouci (CZ) 2017-10-18 EP disclosed
US-4668778-A Nucleoside 5'-alkyl- or alkenylphosphate YAMASA SHOYU KABUSHIKI KAISHA (JP) 1987-05-26 US disclosed
EP-0097376-B1 NUCLEOSIDE 5'-ALKYL- OR ALKENYLPHOSPHATE Yamasa Shoyu Kabushiki Kaisha (JP) 1986-09-17 EP disclosed
EP-0097376-A1 Nucleoside 5'-alkyl- or alkenylphosphate Yamasa Shoyu Kabushiki Kaisha (JP) 1984-01-04 EP disclosed
US-4371613-A TRANSARABINOSYLATION USING AN ENZYME FROM BACTERIA, AN ARABINOSE DONOR AND A PURINE SOURCE AJINOMOTO COMPANY INCORPORATED (JP) 1983-02-01 US disclosed
US-4371613-A TRANSARABINOSYLATION USING AN ENZYME FROM BACTERIA, AN ARABINOSE DONOR AND A PURINE SOURCE AJINOMOTO COMPANY INCORPORATED (JP) 1983-02-01 US disclosed
US-4112221-A HEATING A 2',3'-O-SULFINYL-8-OXYPURINE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1978-09-05 US disclosed
US-4093714-A VIRICIDES ICN PHARMACEUTICALS, INC. (US) 1978-06-06 US disclosed
US-4093714-A VIRICIDES ICN PHARMACEUTICALS, INC. (US) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF GART, DAO, GLA ADA 62/4885KDM4E 1565/4885PKM 2428/4885
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof GART, DAO, GLA ADA 62/4885KDM4E 1565/4885PKM 2428/4885
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNG, FUT6, GART ADA 66/4885KDM4E 2569/4885PKM 3668/4885
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNG, FUT6, GART ADA 66/4885KDM4E 2569/4885PKM 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.